1. Home
  2. LUCD vs EARN Comparison

LUCD vs EARN Comparison

Compare LUCD & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lucid Diagnostics Inc.

LUCD

Lucid Diagnostics Inc.

HOLD

Current Price

$1.00

Market Cap

198.4M

Sector

Health Care

ML Signal

HOLD

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$4.43

Market Cap

169.8M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUCD
EARN
Founded
2018
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
198.4M
169.8M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
LUCD
EARN
Price
$1.00
$4.43
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$4.13
$5.38
AVG Volume (30 Days)
1.7M
382.8K
Earning Date
05-13-2026
06-16-2026
Dividend Yield
N/A
20.51%
EPS Growth
16.67
N/A
EPS
N/A
N/A
Revenue
$4,346,000.00
N/A
Revenue This Year
$115.58
$7.69
Revenue Next Year
$130.54
$19.57
P/E Ratio
N/A
N/A
Revenue Growth
79.00
N/A
52 Week Low
$0.90
$4.27
52 Week High
$1.63
$6.08

Technical Indicators

Market Signals
Indicator
LUCD
EARN
Relative Strength Index (RSI) 47.21 43.74
Support Level $1.01 $4.31
Resistance Level $1.11 $4.78
Average True Range (ATR) 0.05 0.09
MACD -0.00 0.00
Stochastic Oscillator 39.39 34.72

Price Performance

Historical Comparison
LUCD
EARN

About LUCD Lucid Diagnostics Inc.

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.

Share on Social Networks: